Indian Pharma Sector Analysis

India remains one of the world’s major pharmaceutical manufacturing centres, supported by domestic demand and exports. The latest government data shows both scale and continued expansion.

• Industry turnover reached ₹4.72 lakh crore in FY2024-25.
• Pharma exports grew 7.4% in FY2025-26.
• India ranks third globally by pharmaceutical production volume.
• It supplies around 20% of global generic medicine demand.
• Indian medicines reach more than 200 countries.
• Pharma-related PLI schemes have a combined outlay of ₹25,360 crore.
• These schemes have attracted more than ₹51,997 crore of investment.
• Growth areas include complex generics, biosimilars, biologics, and domestic manufacturing of key drug ingredients.
• Investors still need to check margins, regulatory compliance, research spending, exports, and valuation before studying a pharma stock.

Last reviewed: September 2026

Pharma companies earn money from several different businesses, so two companies in the same sector can have very different risks.

API means Active Pharmaceutical Ingredient. It is the main ingredient in a medicine that produces the intended medical effect.

A company that depends heavily on US exports can face different risks from a company that earns mainly from medicines sold in India.

Exports remain an important growth engine for Indian pharmaceutical companies.

Pharmaceutical exports grew 7.4% in FY2025-26.

India now exports medicines to more than 200 countries and supplies around 20% of global generic medicine demand.

A large part of Indian pharma exports also goes to tightly regulated markets.

This creates an opportunity, but also a risk.

A company selling medicines in the US or Europe must meet strict manufacturing and quality standards.

Suppose Ramesh invests in a pharma company that earns a large part of its money from the US.

If the company’s factory receives a serious regulatory warning, it may face:

• delayed product approvals,
• restrictions on new products,
• additional compliance costs,
• slower sales growth.

So export growth alone is not enough.

The useful action is to check where the company exports, how dependent it is on one market, and whether its manufacturing plants have unresolved regulatory issues.

Growth can come from both higher healthcare demand and a shift towards more valuable medicines.

Government policy is increasingly focused on areas such as:

• Complex generics
• Biosimilars
• Biologics
• New drug development
• Active pharmaceutical ingredients
• Medical devices
• Domestic manufacturing

The sector is gradually moving beyond simple, low-cost generic medicines.

This matters because more complex products can create additional revenue opportunities.

However, they can also require more money for:

• research,
• clinical development,
• manufacturing,
• regulatory approvals.

So moving towards higher-value medicines does not automatically mean higher profit.

Investors should check how much a company spends to create that growth and whether successful products generate enough returns.

Government schemes are trying to increase domestic manufacturing and reduce dependence on imported pharmaceutical inputs.

Three Production Linked Incentive, or PLI, schemes covering pharmaceuticals and related areas have a combined budgetary outlay of ₹25,360 crore.

By 2026, these schemes had attracted more than:

₹51,997 crore of investment

They had also generated cumulative sales of about:

₹3.88 lakh crore

This includes more than ₹2.43 lakh crore of exports.

Manufacturing capacity has also been created for 218 APIs, key starting materials, and drug intermediates, along with 57 medical devices.

For an investor, the useful point is not simply that government support exists.

Check whether the individual company you are studying is actually benefiting through:

• new factories,
• higher capacity,
• new products,
• lower import dependence,
• better sales,
• better margins.

Government support to a sector does not guarantee profit for every company in that sector.

Start with how the company earns money rather than whether the overall pharma sector is growing.

Check these eight points:

1. Domestic versus export revenue: Find out which market contributes more.
2. US exposure: Higher US sales can offer opportunity but also bring stricter regulatory risk.
3. Regulatory history: Check warning letters, observations, import restrictions, and resolution status.
4. Profit margins: See whether higher sales are actually producing higher profit.
5. Research spending: Check how much money goes into research and what products may come from it.
6. Product concentration: Avoid judging the business from one successful drug.
7. Debt and cash flow: Check whether growth is producing cash rather than only accounting profit.
8. Valuation: A strong pharma company can still give weak returns if its shares are bought at a very expensive price.

Suppose a pharma company grows revenue by 15%.

That sounds positive.

But if research expenses and manufacturing costs rise so much that profit grows only 2%, an investor should investigate why margins weakened.

The action is simple: compare sales growth, profit growth, margins, regulatory status, and valuation together.

Source: Press Information Bureau, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals